Psilocybin is a psychoactive compound found in over 200 species of mushrooms that activates serotonin receptors in the brain, producing altered perception, emotional shifts, and changes in how brain regions communicate with each other. Its effects typically last six to eight hours, but the changes it triggers in brain structure and connectivity can persist for weeks or even months.
How Psilocybin Works in the Brain
Psilocybin itself is actually a prodrug. Your body rapidly converts it into psilocin, the molecule that does the heavy lifting. Psilocin binds to and activates a specific type of serotonin receptor called 5-HT2A, which is concentrated in areas of the brain involved in perception, mood, and cognition. This receptor is the primary target responsible for the psychological effects. Interestingly, not every molecule that activates this same receptor produces psychedelic effects. Some closely related compounds are used to treat migraines and Parkinson’s disease without causing any hallucinations, which tells researchers that the story is more complex than simple receptor activation.
One of the most striking things psilocybin does is reorganize how brain networks talk to each other. Normally, your brain operates in relatively compartmentalized networks. Psilocybin breaks down those walls. It decreases connectivity within a brain network called the default mode network (the system most active during self-reflection, mind-wandering, and maintaining your sense of identity) while simultaneously increasing connectivity between networks that don’t usually communicate much. Brain imaging studies show that out of tens of thousands of possible connections, hundreds become significantly different from their baseline state. The result is a brain that is, temporarily, less constrained, more flexible, and less locked into habitual patterns of thought.
This disruption of the default mode network appears closely tied to the experience of “ego dissolution,” the feeling that the boundary between yourself and the world has softened or disappeared. People who report the strongest mystical or peak experiences during a session show the greatest decreases in connectivity within this network. Some of these connectivity changes persist. In depressed patients, reduced rigidity in the default mode network has been measured up to three weeks after a single dose.
What It Does to Brain Structure
Beyond temporarily rewiring communication patterns, psilocybin causes physical changes in neurons. A study published in Neuron found that a single dose led to roughly a 10% increase in the size and density of dendritic spines, the tiny protrusions on brain cells where synapses form, in the frontal cortex. This structural remodeling happened fast, within 24 hours, and was still present a month later. About half of the newly formed spines were still stable after a week, and roughly a third persisted past 34 days, suggesting they became functional new connections.
This growth was driven entirely by increased formation of new spines rather than decreased elimination of existing ones. In practical terms, this means psilocybin prompts your brain to build new wiring in the frontal cortex, a region critical for flexible thinking, emotional regulation, and decision-making. This physical rewiring may help explain why the psychological benefits of psilocybin often outlast the drug’s presence in the body by weeks or months.
The Subjective Experience
The effects of psilocybin begin roughly 30 to 60 minutes after ingestion, reach peak intensity around 60 to 120 minutes in, and resolve over the course of six to eight hours total. During the peak, the experience can include visual distortions (objects may breathe, ripple, or display geometric patterns), intensified emotions, a sense of awe or reverence, altered perception of time, and a feeling that the experience is profoundly meaningful yet difficult to put into words.
Researchers measure these experiences using standardized questionnaires that capture four main dimensions: a feeling of unity or connection to something larger than yourself, intense positive mood, the sense of being outside normal time and space, and ineffability. Not all experiences are positive. Clinical studies report that some participants experience anxiety, fear, paranoia, a feeling of losing their mind, or a sensation of dying. In one clinical trial, about 28% of participants reported anxiety and 28% reported nausea in the hours following a dose, with 14% reporting headaches.
Effects on Depression
The most developed area of psilocybin research is depression. A network meta-analysis of randomized, placebo-controlled trials found that psilocybin produced large antidepressant effects, with an effect size (Hedges’ g) of approximately 1.05, which is considerably larger than what’s typical for conventional antidepressants. Significant symptom reduction appeared by day eight after a single administration and continued to strengthen through day fifteen, though no significant effects were seen at day two. Some evidence suggests benefits can persist up to six months.
This timeline is notable. Traditional antidepressants often take four to six weeks to reach full effect and require daily dosing. Psilocybin appears to produce comparable or greater improvement from one or two sessions, with the antidepressant action becoming apparent within the first week.
Effects on Addiction
Psilocybin combined with psychotherapy has shown promising results for alcohol use disorder. In a randomized trial published in JAMA Psychiatry, participants who received psilocybin-assisted therapy showed substantially greater reductions in heavy drinking compared to a control group that received psychotherapy with an active placebo. By the final month of follow-up (weeks 33 to 36), 48% of the psilocybin group was completely abstinent compared to 24% in the control group. For the measure of “no heavy drinking days,” the gap was 63% versus 40%. These effects persisted more than eight months after the psilocybin sessions themselves.
Physical Effects and Cardiovascular Safety
Psilocybin temporarily raises heart rate and blood pressure in a dose-dependent way. In clinical trials, mean peak heart rates typically reach the low-to-mid 80s (beats per minute), and systolic blood pressure peaks around 138 to 155 mmHg at higher doses. For context, a resting heart rate of 82 and blood pressure of 146/93 are mildly elevated but not dangerous for most healthy adults. These increases are transient and have been consistently described in clinical reviews as short-term and clinically non-significant. One study comparing psilocybin to placebo found heart rate went from about 70 beats per minute on placebo to about 82 at the peak of a moderate dose, with blood pressure rising from 117/70 to 139/76.
Psychological Risks
The most commonly discussed long-term risk is hallucinogen persisting perception disorder, or HPPD, a condition where visual disturbances like halos around objects or size distortions continue after the drug has worn off and cause significant distress. Among people who have used psychedelics, about 1.3% report being diagnosed with HPPD, compared to 0.3% among non-users. While real, this remains relatively uncommon.
A more serious concern involves people with a personal or family history of psychotic disorders or bipolar disorder. Clinical trials routinely exclude these individuals because psychedelics may trigger or worsen psychotic episodes. This screening criterion extends to anyone with a first- or second-degree relative (parent, sibling, grandparent, aunt, or uncle) with these conditions. Outside of controlled settings where this screening happens, this risk is harder to manage.
Current Legal and Regulatory Status
Psilocybin remains a Schedule I controlled substance in the United States, meaning it is illegal to manufacture, possess, or distribute outside of approved research. The FDA has granted it breakthrough therapy designation, which accelerates the review process for drugs that show potential for significant improvement over existing treatments. No psychedelic is currently FDA-approved for any condition.
Two organizations are running phase 3 clinical trials for psilocybin. Compass Pathways is testing it for treatment-resistant depression, and the Usona Institute launched its first phase 3 trial for major depressive disorder in March 2024. If these trials succeed, FDA approval could come as early as 2026. The path cleared somewhat after the FDA declined to approve MDMA for PTSD in August 2024, making psilocybin the most likely psychedelic to reach the market first.